Name: Name:2-Amino-5-bromo-4-hydroxy-6-phenylpyrimidine
Brand: AABLOCKS
SKU: AA003GDP
Rating: 90 (10 reviews)

Technical Information

Catalog Number: AA003GDP

Chemical Name: 2-Amino-5-bromo-4-hydroxy-6-phenylpyrimidine

CAS Number: 56741-95-8

Molecular Formula: C10H8BrN3O

Molecular Weight: 266.0940

MDL Number: MFCD00813905

SMILES: O=c1nc(N)[nH]c(c1Br)c1ccccc1

NSC Number: 149027

Properties

BP: 389.7°C at 760 mmHg

Form: Solid

MP: 268 - 270 °C

Refractive Index: 1.6520 (estimate)

Solubility: DMSO: ≥5mg/mL (warm DMSO)

Storage: Light sensitive;Inert atmosphere;2-8℃;

Complexity: 343

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 0

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 15

Hydrogen Bond Acceptor Count: 2

Hydrogen Bond Donor Count: 2

Isotope Atom Count: 0

Rotatable Bond Count: 1

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 1.2

Literature fold

Title: The expression and functions of toll-like receptors in atherosclerosis.

Journal: Mediators of inflammation20100101

Title: Toll-like receptors: role in dermatological disease.

Journal: Mediators of inflammation20100101

Title: Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party.

Journal: World journal of urology20090601

Title: A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study.

Journal: Urologic oncology20050101

Title: Current state of immunotherapy for bladder cancer.

Journal: Expert review of anticancer therapy20041201

Title: Current and new strategies in immunotherapy for superficial bladder cancer.

Journal: Urology20040901

Title: Superficial bladder cancer therapy.

Journal: TheScientificWorldJournal20040101

Title: Characterization of bropirimine O-glucuronidation in human liver microsomes.

Journal: Xenobiotica; the fate of foreign compounds in biological systems20031001

Title: Recognition of pathogen-associated molecular patterns by TLR family.

Journal: Immunology letters20030122

Title: In vitro antitumor activity of bropirimine against urinary bladder tumor cells.

Journal: Anticancer research20020101

Title: The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.

Journal: The Journal of urology20010301

Title: Immunotherapy for bladder cancer.

Journal: Current urology reports20010201

Title: Lack of interaction between bropirimine and 5-fluorouracil on human dihydropyrimidine dehydrogenase.

Journal: Xenobiotica; the fate of foreign compounds in biological systems20010101

Title: Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections.

Journal: Antiviral research19941001

Title: Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine.

Journal: Cancer research19900215

Title: Pyrimidinones. 1. 2-Amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-inducing antiviral agents.

Journal: Journal of medicinal chemistry19851201

Title: Antiviral and other bioactivities of pyrimidinones.

Journal: Pharmacology & therapeutics19850101

Title: 5-substituted 2-amino-6-phenyl-4(3H)-pyrimidinones. Antiviral- and interferon-inducing agents.

Journal: Journal of medicinal chemistry19800301

Title: Suzuki H, et al. Bropirimine inhibits osteoclast differentiation through production of interferon-β. Biochem Biophys Res Commun. 2015;467(1):146‐151.

Title: Sarosdy MF, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. Urology. 1998;51(2):226‐231.

56741-95-8 | 2-Amino-5-bromo-4-hydroxy-6-phenylpyrimidine